Murphy Glenn S, Szokol Joseph W, Franklin Mark, Marymont Jesse H, Avram Michael J, Vender Jeffery S
*Department of Anesthesiology, Evanston Northwestern Healthcare, Northwestern University Feinberg School of Medicine, Evanston, Illinois; and †Department of Anesthesiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Anesth Analg. 2004 Jan;98(1):193-200. doi: 10.1213/01.ANE.0000095040.36648.F7.
In this study, we examined the effect of choice of neuromuscular blocking drug (NMBD) (pancuronium versus rocuronium) on postoperative recovery times and associated adverse outcomes in patients undergoing orthopedic surgical procedures. Seventy patients were randomly allocated to a pancuronium or rocuronium group. On arrival to the postanesthesia care unit (PACU) and again 30 min later, train-of-four ratios were quantified by using acceleromyography. Immediately after acceleromyographic measurements, patients were assessed for signs and symptoms of residual paresis. During the PACU admission, episodes of hypoxemia, nausea, and vomiting were recorded. The time required for patients to meet discharge criteria and the time of actual PACU discharge were noted. Forty percent of patients in the pancuronium group had train-of-four ratios <0.7 on arrival to the PACU, compared with only 5.9% of subjects in the rocuronium group (P < 0.001). Patients in the pancuronium group were more likely to experience symptoms of muscle weakness (blurry vision and generalized weakness; P < 0.001) and hypoxemia (10 patients in the rocuronium group versus 21 patients in the pancuronium group; P = 0.015) during the PACU admission. Significant delays in meeting PACU discharge criteria (50 min [45-60 min] versus 30 min [25-40 min]) and achieving actual discharge (70 min [60-90 min] versus 57.5 min [45-61 min]) were observed when the pancuronium group was compared with the rocuronium group (P < 0.001). In conclusion, our study indicates that PACU recovery times may be prolonged when long-acting NMBDs are used in surgical patients.
Clinical recovery may be delayed in surgical patients administered long-acting neuromuscular blocking drugs. During the postanesthesia care unit admission, patients randomized to receive pancuronium (versus rocuronium) were more likely to exhibit symptoms of muscle weakness, develop hypoxemia, and require more time to meet discharge criteria.
在本研究中,我们探讨了神经肌肉阻滞药物(NMBD)的选择(泮库溴铵与罗库溴铵)对接受骨科手术患者术后恢复时间及相关不良结局的影响。70例患者被随机分配至泮库溴铵组或罗库溴铵组。到达麻醉后护理单元(PACU)时及30分钟后,使用加速度肌电图对四个成串刺激比值进行量化。在加速度肌电图测量后,立即对患者进行残余麻痹的体征和症状评估。在PACU住院期间,记录低氧血症、恶心和呕吐发作情况。记录患者达到出院标准所需时间及实际从PACU出院的时间。泮库溴铵组40%的患者到达PACU时四个成串刺激比值<0.7,而罗库溴铵组仅为5.9%(P<0.001)。泮库溴铵组患者在PACU住院期间更易出现肌肉无力症状(视物模糊和全身无力;P<0.001)及低氧血症(罗库溴铵组10例患者,泮库溴铵组21例患者;P=0.015)。与罗库溴铵组相比,泮库溴铵组在达到PACU出院标准(50分钟[45 - 60分钟]对30分钟[25 - 40分钟])及实际出院(70分钟[60 - 90分钟]对57.5分钟[45 - 61分钟])方面存在显著延迟(P<0.001)。总之,我们的研究表明,手术患者使用长效NMBD时,PACU恢复时间可能延长。
接受长效神经肌肉阻滞药物的手术患者临床恢复可能延迟。在麻醉后护理单元住院期间,随机接受泮库溴铵(与罗库溴铵相比)的患者更易出现肌肉无力症状、发生低氧血症,且需要更多时间达到出院标准。